ProMeris
metaflumizone
Table of contents
Overview
The marketing authorisation for ProMeris has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
ProMeris
|
| Agency product number |
EMEA/V/C/000107
|
| Active substance |
metaflumizone
|
| International non-proprietary name (INN) or common name |
metaflumizone
|
| Species |
Cats
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QP53AX25
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Pfizer Limited
|
| Revision |
8
|
| Date of issue of marketing authorisation valid throughout the European Union |
19/12/2006
|
| Contact address |
Pfizer Limited
Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom |
Product information
08/07/2015 ProMeris - EMEA/V/C/000107 - IB/0012
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Ectoparasiticides for topical use, incl. insecticides
Therapeutic indication
Treatment and prevention of flea infestations (Ctenocephalides canis and C. felis) in cats. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).